Replies to post #135483 on Biotech Values

[iwfal]

CLDX -

If I remember from looking earlier in the day, the median number of preceding treatments for the Eribulan P3 was 4. For the CDX-011 BC trial it is a remarkable 7. I'd expect that to have a meaningful effect on background rate of ORR.

A calibration of the difference between the ORR for a drug in refractory and first line:

Tarceva

a) in refractory NSCLC - 13.5% (7/52)
b) in first line NSCLC - 22.7% (12/53)

http://theoncologist.alphamedpress.org/content/12/7/840.full


Looking for monotherapy differences in ORR between 3rd line and 1st line and hard to find. FWIW.